MSRA: A Drug Target and Biomarker for Cancer (G4482)

Target Name: MSRA

NCBI ID: G4482

MSRA

MSRA: A Drug Target and Biomarker for Cancer

MSRA (Mesothelin-Specific Recombinant Antibody) is a drug target and biomarker that is used to measure the levels of mesothelin, a protein that is found on the surface of many cancer cells. Mesothelin is often used as a biomarker for cancer because it is highly expressed in many types of cancer, and it has been shown to be a useful predictor of cancer outcomes.

One of the main advantages of MSRA is its ability to provide accurate and reliable measurements of mesothelin levels in a variety of samples, including cancer cell samples, patient tissue samples, and biological fluids. This is important because mesothelin levels can be difficult to measure accurately in some types of cancer, and accurate measurements are essential for evaluating the effectiveness of new treatments.

In addition to its use as a drug target and biomarker, MSRA is also being studied for its potential use as a diagnostic tool. Some studies have shown that MSRA can be used to diagnose mesothelin-positive breast cancer, a type of cancer that is particularly difficult to diagnose due to its lack of specific symptoms.

The use of MSRA as a drug target is still in the early stages of research, but it holds great promise as a potential treatment for a variety of cancers. One of the main advantages of MSRA is its ability to target mesothelin specifically, rather than other proteins that may be found on the surface of cancer cells. This allows for more precise and effective treatment of cancer.

In addition to its potential use as a drug target, MSRA is also being studied for its potential use as a biomarker in cancer. By measuring the levels of mesothelin in cancer cells and patient tissue samples, researchers can gain insights into the effectiveness of different treatments and monitor the progress of cancer over time.

Overall, MSRA is a drug target and biomarker that has the potential to revolutionize the treatment of cancer. With further research and development, it is likely that MSRA will be used to treat a wide range of cancer types and will become a valuable tool for cancer researchers and clinicians.

Protein Name: Methionine Sulfoxide Reductase A

Functions: Has an important function as a repair enzyme for proteins that have been inactivated by oxidation. Catalyzes the reversible oxidation-reduction of methionine sulfoxide in proteins to methionine

The "MSRA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MSRA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets